CSBio CSBio

X
[{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Confirms the Stability and Potency of a Novel Formulation of Liquid Levothyroxine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"IBSA Institut Biochimique"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IBSA Pharma and Mark Cuban Cost Plus Drug Company Team Up to Make Tirosint More Affordable","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"IBSA Institut Biochimique"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Signs Agreement with Novartis for Diabetes Therapy Galvus Range","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"USV Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supplier can only Seek Advance Ruling under GST, Rules MAAR","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$99.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Two Significant Agreements with Sandoz for China and Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Sandoz B2B"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

            Lead Product(s): Octreotide Acetate

            Therapeutic Area: Endocrinology Product Name: Sandostatin LAR Depot

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Aspen Pharmacare Holdings

            Deal Size: $99.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement December 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Cipla will manufacture and market Galvus (vildagliptin) and Galvus combination brands, used in the treatment of type 2 diabetes.

            Lead Product(s): Vildagliptin

            Therapeutic Area: Endocrinology Product Name: Galvus

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cipla

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tirosint capsules is the leading branded gel capsule formulation of levothyroxine sodium in the US. It is formulated without excipients that can cause tolerability and drug absorption problems commonly observed with traditional levothyroxine tablet therapies.

            Lead Product(s): Levothyroxine Sodium

            Therapeutic Area: Endocrinology Product Name: Tirosint

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mark Cuban Cost Plus Drug Company

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, USV acquires the trademark for antidiabetes drug Jalra (vildagliptin) and Jalra M (vildagliptin and metformin), used to treat type 2 diabetes mellitus, from Novartis.

            Lead Product(s): Vildagliptin

            Therapeutic Area: Endocrinology Product Name: Jalra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: USV Private Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The study examined the potency and consistency of Tirosint-SOL marketed by IBSA Pharma Inc, using the same methodology as the previous study to determine the degree to which the product maintains its labeled potency over a five-week period.

            Lead Product(s): Levothyroxine Sodium

            Therapeutic Area: Endocrinology Product Name: Tirosint-SOL

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY